Genomenon’s cardiology gene panel, consisting of 143 consensus genes, is designed to support advancements in cardiovascular genomics. Our curation of these genes provides a detailed review of cardiology-related genetic data, offering clinicians and researchers valuable insights into the genetic factors underlying heart disease and helping improve diagnostics and treatment approaches.

‍

A Rigorous Foundation for Precision Medicine

‍

Genomenon’s cardiology gene panel is built on rigorous gene-disease relationship analysis and insights from leading molecular diagnostic laboratories. It includes genes associated with arrhythmias (disruptions in electrical impulses), cardiomyopathies (structural heart abnormalities), and syndromic conditions with cardiovascular phenotypes. By also incorporating all ACMG secondary findings cardiology genes, this panel ensures alignment with clinical guidelines. These genes are critical for identifying at-risk individuals and guiding preventive care.

‍

Unparalleled Curation and Accuracy

‍

In response to user feedback and upcoming updates to the ACMG sequence interpretation guidelines, Genomenon has refined its curation process to elevate the quality of curated evidence. This enhanced approach provides a deeper understanding of variant impact by incorporating a broader range of data points rather than relying solely on rigid criteria. We remain committed to improving transparency, offering users clear insights into the rationale behind the inclusion or exclusion of evidence, all while maintaining a seamless interface and user experience. These updates ensure that each variant is curated to the highest standards of accuracy and clinical relevance. As a result, the panel supports faster identification of pathogenic variants, enabling healthcare providers to make well-informed decisions and advance precision medicine.

‍

Bridging Research and Clinical Practice

‍

The curated gene panel not only advances diagnostics but also acts as a powerful resource for researchers. It facilitates the study of gene-disease relationships, opening new avenues for discovery in cardiovascular genetics. For clinicians, it serves as a reliable tool to provide personalized care, aligning research insights with practical applications. By connecting these two domains, Genomenon’s cardiology panel helps focus efforts where they matter most: improving and saving lives.

‍

‍

ACMG Secondary Findings: A Closer Look

‍

A standout feature of the panel is its inclusion of ACMG secondary findings cardiology genes, as recommended by the American College of Medical Genetics and Genomics. These genes carry actionable health implications, even when identified incidentally. Genomenon’s comprehensive review of these genes ensures that users are equipped to address life-altering conditions with a proactive approach.

‍

Pioneering the Future of Cardiovascular Genomics

‍

The development of this cardiology gene panel represents a significant step forward in cardiovascular care. It meets today’s research and clinical needs while anticipating tomorrow’s challenges. By providing high-quality genetic data, Genomenon is enabling more accurate diagnoses, effective treatments, and better outcomes for patients. This effort reflects a broader commitment to advancing genomic intelligence and bringing precision medicine into routine care.

‍

‍

Partner With Us to Transform Care

‍

Genomenon’s cardiology gene panel is designed to support clinicians, researchers, and diagnostic labs in their pursuit of better patient care. Whether you’re uncovering gene-disease relationships, diagnosing complex conditions, or developing personalized therapies, this panel is a powerful tool to guide your work.

‍

‍Visit Mastermind, our genomic intelligence platform to learn more, or reach out to explore how Genomenon can help you advance the future of cardiovascular genomics.